Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 2778

1.

Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy.

Wykoff CC.

Curr Opin Ophthalmol. 2017 May;28(3):213-218. doi: 10.1097/ICU.0000000000000364. Review.

PMID:
28376510
2.

Soluble fms-Like Tyrosine Kinase 1 as a Link Between Angiogenesis and Endothelial Dysfunction in Pediatric Patients With β-Thalassemia Intermedia.

Tantawy AA, Adly AA, Ismail EA, Youssef OI, Ali ME.

Clin Appl Thromb Hemost. 2017 Jan 1:1076029617692879. doi: 10.1177/1076029617692879. [Epub ahead of print]

PMID:
28301910
3.

Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.

Shen W, Yau B, Lee SR, Zhu L, Yam M, Gillies MC.

Int J Mol Sci. 2017 Mar 1;18(3). pii: E533. doi: 10.3390/ijms18030533.

4.

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

Tannir NM, Schwab G, Grünwald V.

Curr Oncol Rep. 2017 Feb;19(2):14. doi: 10.1007/s11912-017-0566-9. Review.

5.

Paracrine effect of CXCR4-overexpressing mesenchymal stem cells on ischemic heart injury.

Wu SZ, Li YL, Huang W, Cai WF, Liang J, Paul C, Jiang L, Wu ZC, Xu M, Zhu P, Wang Y.

Cell Biochem Funct. 2017 Mar;35(2):113-123. doi: 10.1002/cbf.3254. Epub 2017 Feb 23.

PMID:
28233339
6.

Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.

Wang J, Qin B, Chen X, Wagner WR, Villanueva FS.

Mol Pharm. 2017 Mar 6;14(3):781-790. doi: 10.1021/acs.molpharmaceut.6b01033. Epub 2017 Feb 15.

7.

Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.

Akatsu Y, Yoshimatsu Y, Tomizawa T, Takahashi K, Katsura A, Miyazono K, Watabe T.

Cancer Sci. 2017 Jan;108(1):151-155. doi: 10.1111/cas.13103.

8.

Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.

Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E.

Cancer Treat Rev. 2017 Feb;53:120-127. doi: 10.1016/j.ctrv.2016.12.002. Epub 2016 Dec 30. Review.

PMID:
28104567
9.

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+/- Mice Is Superior to Everolimus Alone.

Yang J, Samsel PA, Narov K, Jones A, Gallacher D, Gallacher J, Sampson JR, Shen MH.

Neoplasia. 2017 Feb;19(2):112-120. doi: 10.1016/j.neo.2016.12.008. Epub 2017 Jan 13.

10.

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma.

Dai J, Wu S, Kong Y, Chi Z, Si L, Sheng X, Cui C, Fang J, Zhang J, Guo J.

Sci Rep. 2017 Jan 5;7:39597. doi: 10.1038/srep39597.

11.

Tetramethylpyrazine attenuates carbon tetrachloride-caused liver injury and fibrogenesis and reduces hepatic angiogenesis in rats.

Zhao S, Zhang Z, Qian L, Lin Q, Zhang C, Shao J, Zhang F, Zheng S.

Biomed Pharmacother. 2017 Feb;86:521-530. doi: 10.1016/j.biopha.2016.11.122. Epub 2016 Dec 23.

PMID:
28024287
12.

A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.

Stubbs C, Bardoli AD, Afshar M, Pirrie S, Miscoria M, Wheeley I, Porfiri E.

Anticancer Res. 2017 Jan;37(1):253-259.

PMID:
28011500
13.

PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.

Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M, Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T.

Retina. 2017 Jan;37(1):179-190. doi: 10.1097/IAE.0000000000001117.

PMID:
28005721
14.

The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.

Melsens E, Verberckmoes B, Rosseel N, Vanhove C, Descamps B, Pattyn P, Ceelen W.

Eur Surg Res. 2017;58(3-4):95-108. doi: 10.1159/000452741. Epub 2016 Dec 22.

PMID:
28002822
15.

The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.

Takano S, Ishikawa E, Matsuda M, Sakamoto N, Akutsu H, Yamamoto T, Matsumura A.

Int J Oncol. 2017 Feb;50(2):515-524. doi: 10.3892/ijo.2016.3810. Epub 2016 Dec 19.

PMID:
28000842
16.

The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.

Morris KA, Afridi SK, Evans DG, Hensiek AE, McCabe MG, Kellett M, Halliday D, Pretorius PM, Parry A; , on behalf of the UK NF2 Research Group..

J Neurosurg Spine. 2017 Apr;26(4):474-482. doi: 10.3171/2016.8.SPINE16589. Epub 2016 Dec 16.

PMID:
27982762
17.

Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Zhu Y, Zhang T, Xu G, Peng L.

Cochrane Database Syst Rev. 2016 Dec 15;12:CD011160. doi: 10.1002/14651858.CD011160.pub2. Review.

PMID:
27977064
18.

Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.

Kurzrock R, Stewart DJ.

Clin Cancer Res. 2017 Mar 1;23(5):1137-1148. doi: 10.1158/1078-0432.CCR-16-1968. Epub 2016 Dec 9. Review.

PMID:
27940520
19.

Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report.

Raheja A, Colman H, Palmer CA, Couldwell WT.

J Neurosurg. 2016 Dec 9:1-6. doi: 10.3171/2016.9.JNS161629. [Epub ahead of print]

PMID:
27935362
20.

Cabozantinib: A Review in Advanced Renal Cell Carcinoma.

Al-Salama ZT, Keating GM.

Drugs. 2016 Dec;76(18):1771-1778. Review.

PMID:
27909994

Supplemental Content

Loading ...
Support Center